MedTrace Logo

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

NCT07082816 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 489

Last updated 2026-04-21

No results posted yet for this study

Summary

This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Conditions

Interventions

DRUG

Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution

Investigational ophthalmic solution

DRUG

Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution

Commercially available ophthalmic solution

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Clinical Trial Lead, Pharma · Alcon Research, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-02
Primary Completion
2026-04-06
Completion
2026-04-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07082816 on ClinicalTrials.gov